This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellamy, M. F. Articles by Enriquez-Sarano, M. Search for Related Content PubMed PubMed Citation Articles by Bellamy, M. F. Articles by Enriquez-Sarano, M.

Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community

^* Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

View larger version (23K): [in a new window]   Figure 1 Annualized progression in mean gradient (Mean Grad), peak velocity (Vmax), and aortic valve area (AVA) by quartile of total cholesterol (TChol) concentration in subjects not receiving lipid-lowering treatment. The circles and vertical bars indicate means and standard errors. BSA = body surface area.

View larger version (22K): [in a new window]   Figure 2 Association of statin treatment with slower progression of aortic stenosis (AS) as shown by odds ratios and 95% confidence intervals <1 for criteria of progression. The odds ratios are indicated by the circles (for the overall population) and by squares (for patients with systematic follow-up [F-U] not motivated by symptomatic progression) with their 95% confidence interval (continuous and dashed line, respectively). Progression criteria are defined by median in the population for (top to bottom) mean gradient (Mean grad), peak transaortic velocity (Vmax), dimensionless index (Index), aortic valve area (AVA), and aortic valve area standardized to body surface area (AVA/BSA). The directions of the changes are indicated by the arrows: upward for increases, downward for decreases.